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CLINICAL AND POPULATION SCIENCES
Admission Blood Pressure in Relation to Clinical 
Outcomes and Successful Reperfusion After 
Endovascular Stroke Treatment
Sophie A. van den Berg , MD*; Simone M. Uniken Venema , MD*; Maxim J.H.L. Mulder, MD, PhD; Kilian M. Treurniet , MD; 
Noor Samuels, MD; Hester F. Lingsma, PhD; Robert-Jan B. Goldhoorn , MD; Ivo G.H. Jansen, MD, PhD;  
Jonathan M. Coutinho, MD, PhD; Bob Roozenbeek, MD, PhD; Diederik W.J. Dippel, MD, PhD; Yvo B.W.E.M. Roos, MD, PhD;  
H. Bart van der Worp, MD, PhD; Paul J. Nederkoorn, MD, PhD; on behalf of the MR CLEAN Registry Investigators†
BACKGROUND AND PURPOSE: Optimal blood pressure (BP) targets before endovascular treatment (EVT) for acute ischemic 
stroke are unknown. We aimed to assess the relation between admission BP and clinical outcomes and successful 
reperfusion after EVT.
METHODS: We used data from the MR CLEAN (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands) Registry, an observational, prospective, nationwide cohort study of patients with ischemic 
stroke treated with EVT in routine clinical practice in the Netherlands. Baseline systolic BP (SBP) and diastolic BP (DBP) were 
recorded on admission. The primary outcome was the score on the modified Rankin Scale at 90 days. Secondary outcomes 
included successful reperfusion (extended Thrombolysis in Cerebral Infarction score 2B-3), symptomatic intracranial 
hemorrhage, and 90-day mortality. Multivariable logistic and linear regression were used to assess the associations of SBP 
and DBP with outcomes. The relations between BPs and outcomes were tested for nonlinearity. Parameter estimates were 
calculated per 10 mm Hg increase or decrease in BP.
RESULTS: We included 3180 patients treated with EVT between March 2014 and November 2017. The relations between 
admission SBP and DBP with 90-day modified Rankin Scale scores and mortality were J-shaped, with inflection 
points around 150 and 81 mm Hg, respectively. An increase in SBP above 150 mm Hg was associated with poor 
functional outcome (adjusted common odds ratio, 1.09 [95% CI, 1.04–1.15]) and mortality at 90 days (adjusted odds 
ratio, 1.09 [95% CI, 1.03–1.16]). Following linear relationships, higher SBP was associated with a lower probability 
of successful reperfusion (adjusted odds ratio, 0.97 [95% CI, 0.94–0.99]) and with the occurrence of symptomatic 
intracranial hemorrhage (adjusted odds ratio, 1.06 [95% CI, 0.99–1.13]). Results for DBP were largely similar.
CONCLUSIONS: In patients with acute ischemic stroke treated with EVT, higher admission BP is associated with lower probability 
of successful reperfusion and with poor clinical outcomes. Further research is needed to investigate whether these patients 
benefit from BP reduction before EVT.
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In patients with acute ischemic stroke and a proxi-mal occlusion of an intracranial artery of the ante-rior circulation, endovascular treatment (EVT) 
increases the chance of a good functional out-
come.1,2 Still, about half of the patients treated with 
EVT remain functionally dependent or die,3 in part, 
because of unsuccessful reperfusion or the occur-
rence of symptomatic intracranial hemorrhage (sICH). 
Further optimization of current treatment strate-
gies is, therefore, warranted. A potential strategy for 
improving outcome after EVT is early blood pressure 
(BP) modification.
In the acute phase of stroke, hypertension is com-
mon4,5 and may serve as a compensatory mechanism 
to increase blood flow to the ischemic area.6 In general 
populations of patients with acute ischemic stroke and 
in those with a large vessel occlusion, J- and U-shaped 
curves have been described for the relation between BP 
and clinical outcomes, where both low and high systolic 
BPs (SBP) were associated with poor outcome.4,7,8 Given 
the wide range of reported optimum baseline SBP and 
diastolic BP (DBP) values, it is likely that optimal BP tar-
gets vary across patients and stroke subtypes.6 In some 
studies, higher SBP was associated with an increased 
risk of sICH.7,9
In line with these uncertainties, BP manage-
ment in the acute phase of ischemic stroke remains 
an unresolved and controversial issue, especially in 
the era of EVT.10 There is insufficient information on 
the relationship between BP and the probability of 
successful reperfusion after EVT. A previous study 
showed that the benefit of EVT is consistent across 
the entire range of SBP.7 However, there is no con-
sensus on the optimal BP targets for patients with 
large vessel occlusion eligible for EVT. We aimed to 
assess the relationship of admission BP with clini-
cal outcomes and successful reperfusion in patients 
with ischemic stroke treated with EVT in routine 
clinical practice.
METHODS
Study Protocol and Data Availability
We used data from the MR CLEAN (Multicenter Randomized 
Controlled Trial of Endovascular Treatment for Acute Ischemic 
Stroke in the Netherlands) Registry,3 a prospective, observational 
cohort study of consecutive patients with ischemic stroke under-
going EVT in the Netherlands. Registration started after the final 
randomization in March 2014 in the MR CLEAN trial.11 The 17 
intervention centers that participated in the MR CLEAN trial pro-
spectively registered consecutive patients treated with EVT for 
acute ischemic stroke. Source data will not be made available 
since no patient approval was obtained for sharing anonymized 
data. However, detailed analytic methods and study materials, 
including output files of statistical analyses, will be made avail-
able to other researchers on request to the first author.
Patients
We included all consecutive patients treated with EVT between 
March 16, 2014, and November 1, 2017, who had a groin 
puncture within 6.5 hours after stroke onset, were aged 18 
years or older, and had intracranial proximal arterial occlusion 
in the anterior circulation (intracranial carotid artery-T or middle 
[M1/M2] or anterior [A1/A2] cerebral artery), demonstrated by 
computed tomography angiography.
Clinical and Radiological Definitions
Admission SBP and DBP were defined as the first recorded 
noninvasive SBP and DBP measured as part of routine clinical 
care on admission to the emergency department. The type of 
BP measurement for each individual patient was not recorded 
in the electronic patient records, but the use of an automated 
sphygmomanometer is common practice in all participating 
centers. EVT was defined as a groin puncture in the angiogra-
phy suite, and the method of EVT for each individual patient was 
left to the discretion of the treating interventionist. All imaging 
was assessed at an imaging core laboratory, consisting of 20 
trained interventional neuroradiologists and one interventional 
neurologist blinded to clinical findings, except for the side of 
symptoms. Successful reperfusion was defined as a score on 
the extended Thrombolysis in Cerebral Infarction scale ≥2B. 
The extended Thrombolysis in Cerebral Infarction scale ranges 
from 0 (no antegrade reperfusion of the occluded vascular ter-
ritory) to 3 (complete antegrade reperfusion).12
Every intracerebral hemorrhage was assessed by the MR 
CLEAN Registry complication committee through evaluation of 
medical reports and imaging and scored as sICH based on the 
Heidelberg criteria.13
Outcome Measures
The primary outcome was the score on the modified Rankin 
Scale (mRS) at 90 days.14 The mRS is a measure of func-
tional outcome after stroke, ranging from 0 (no symptoms) to 
6 (death). Secondary outcomes were excellent (mRS score 
0–1), good (mRS score 0–2), or favorable (mRS score 0–3) 
functional outcome at 90 days, mortality at 90 days, success-
ful reperfusion after EVT, stroke severity (National Institutes of 
Health Stroke Scale [NIHSS] score) at 24 to 48 hours after the 
intervention, and the occurrence of an sICH.
Nonstandard Abbreviations and Acronyms
BP blood pressure
DBP diastolic blood pressure
EVT endovascular treatment
MR CLEAN  Multicenter Randomized Controlled 
Trial of Endovascular Treatment 
for Acute Ischemic Stroke in the 
Netherlands
mRS modified Rankin Scale
NIHSS  National Institutes of Health Stroke 
Scale
SBP systolic blood pressure
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Statistical Analysis
Baseline characteristics and outcomes of the study popula-
tion were compared according to their admission SBP, dichot-
omized at the inflection value of the nonlinear relationship 
between BP and functional outcome. χ2 tests were used for 
categorical variables and Wilcoxon rank-sum test or 2 sample 
t test for continuous variables.
To examine the relations between admission BP and clini-
cal and radiographic outcomes, we tested which model best 
fitted the data by comparing the likelihood ratios of a univari-
able linear function with a model including restricted cubic 
splines or a quadratic term for the BP parameter. When model 
fit was not improved by transformation of the BP parameter, 
a linear model was chosen and regression analysis was per-
formed on the whole population. When a nonlinear relation-
ship between BP and the outcome measure was found, the 
inflection value of the nonlinear model was used as a ref-
erence point, and regression analyses were performed on 2 
subgroups to estimate the differential effects of lower and 
higher ranges of BP on functional outcome. To assess which 
BP parameter (SBP or DBP) had the best correlation with the 
mRS at 90 days, we used the Akaike Information Criterion. 
The model that best fitted the relation of BP with functional 
outcome was used for further analysis.
We performed multivariable ordinal logistic regression, 
binary logistic regression, or linear regression analyses, as 
appropriate, for each outcome variable. We adjusted for a lim-
ited set of potential confounders, identified by a directed acy-
clic graph made by the authors specifically for the purpose of 
the current analyses.15,16 For functional outcome and mortality 
at 90 days and for the occurrence of sICH, we adjusted for age, 
history of hypertension, and NIHSS score at baseline (Figure I 
in the Data Supplement). Analyses for successful reperfusion 
were adjusted for age and NIHSS score. In a post hoc analysis, 
we also adjusted for the presence of ipsilateral carotid steno-
sis of 50% or greater or occlusion. In exploratory analyses, we 
assessed whether the relations of baseline SBP with mRS and 
sICH were modified by successful reperfusion, by adding an 
interaction term to the multivariable logistic regression model 
or performing the analyses on subgroups. The association of 
baseline BP parameters with each clinical outcome were calcu-
lated per 10 mm Hg increase or decrease in BP and expressed 
as odds ratios, common odds ratios, or β coefficients with 
accompanying 95% CI.
Missing values, including missing BP values, were replaced 
with multiple imputation (n=5) based on relevant variables and 
outcomes using AregImpute. All descriptive analyses include 
patients with complete data, whereas all regression analyses 
were performed after multiple imputation. Statistical analyses 
were performed with R software (Version 3.6.1 R Foundation).17
Ethics Approval and Informed Consent
The institutional review board of the Erasmus Medical Center 
Rotterdam, the Netherlands, considered the MR CLEAN 
Registry as a registry study, and therefore, the requirement 
of written informed consent was waived. However, all patients 
were provided with information on the study in writing and 
orally and were given the opportunity to refuse participation. 




Of 3637 patients treated with EVT in the Netherlands 
during the study period, 3180 were included in the cur-
rent analysis (Figure II in the Data Supplement). Admis-
sion SBP was available for 3092 patients (97%) and 
DBP for 3084 patients (97%). An mRS score at 90 days 
was available for 2968 patients (94%). Among those 
with known admission SBP, the median age was 72 
(interquartile range, 61–81) years and 1482 (48%) were 
male. The mean admission SBP and DBP were 150 
mm Hg (SD 25) and 82 mm Hg (SD 16), respectively.
Figure 1. Distribution of scores on the modified Rankin Scale (mRS) at 90 d for patients with admission systolic blood pressure 
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Compared with patients with an admission SBP <150 
mm Hg, patients with an admission SBP ≥150 mm Hg 
were older, more frequently had a medical history of 
diabetes or hypertension or used antihypertensive med-
ication, and smoked less often (Table I in the Data Sup-
plement). Patients with SBP ≥150 mm Hg had slightly 
longer onset-to-groin and onset-to-reperfusion times 
compared with those with SBP <150 mm Hg (190 ver-
sus 196 and 246 versus 255 minutes, respectively). Of 
the 1535 patients with SBP <150 mm Hg, 835 (54%) 
were transferred from a primary stroke center to an inter-
vention center versus 851 of 1557 (55%) of those with 
SBP ≥150 mm Hg. Patients with admission SBP ≥150 
mm Hg had a higher median mRS score and a higher rate 
Table 1. Outcomes According to Admission SBP
All patients,* n=3092
SBP<150 mm Hg, 
n=1535/3092
SBP≥150 mm Hg, 
n=1557/3092 P value†
Primary outcome
 mRS score at 90 d, median (IQR) 3 (2–6) 3 (2–5) 4 (2–6) <0.001
Secondary outcomes
 mRS score 0–1 at 90 d, n (%) 663/2896 (23) 345/1435 (24) 301/1461 (21) 0.03
 mRS score 0–2 at 90 d, n (%) 1200/2896 (41) 629/1435 (44) 541/1461 (37) <0.001
 mRS score 0–3 at 90 d, n (%) 1595/2896 (55) 843/1435 (59) 717/1461 (49) <0.001
 Mortality at 90 d, n (%) 836/2896 (29) 351/1435 (25) 485/1461 (33) <0.001
 Successful reperfusion, n (%)‡ 1851/3011(62) 959/1498 (64) 892/1513 (59) 0.004
 TICI score, n (%) 0.03
  0 508/3011 (17) 231/1498 (15) 277/1513 (18)  
  1 90/3011 (3) 37/1498 (3) 53/1513 (4)  
  2A 563/3011 (19) 271/1498 (18) 292/1513 (19)  
  2B 663/3011(22) 344/1498 (23) 324/1513 (21)  
  2C 323/3011 (11) 158/1498 (11) 165/1513 (11)  
  3 859/3011 (29) 457/1498 (31) 402/1513 (27)  
NIHSS at 24–48 h, median (IQR) 10 (4–17) 9 (3–16) 11 (4–17) <0.001
Symptomatic intracranial hemorrhage, n (%) 184/3092 (6) 69/1535 (5) 115/1557 (7) <0.001
IQR indicates interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; 
and TICI, Thrombolysis in Cerebral Infarction.
*All patients with known SBP.
†P value for difference between the 2 SBP groups: SBP<150 vs SBP≥150.
‡Successful reperfusion indicates scores TICI 2B, 2C, or 3.
Figure 2. Relationship of baseline systolic (SBP) and diastolic blood pressure (DBP) with the probability of poor functional 
outcome (modified Rankin Scale [mRS] score 3–6) 90 d poststroke.
Both models fitted with a restricted cubic spline transformation with 3 knots and are adjusted for National Institutes of Health Stroke Scale (NIHSS) 
at baseline, age, and history of hypertension. The figures depict the probability of poor outcome (mRS score 3–6) with 95% CI, for each level of 
baseline SBP (A) and DBP (B). The depicted relationships are derived from the ordinal model with the full-range mRS score as the outcome variable. 
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of death at 90 days, as well as a higher NIHSS score at 
24 to 48 hours, a higher rate of sICH, and a lower rate 
of successful reperfusion compared with patients with 
admission SBP <150 mm Hg (Figure 1 and Table 1).
Baseline BP and 90-Day Functional Outcome
The association between admission SBP or DBP and 
functional outcome at 90 days (mRS shift analysis) 
was nonlinear. Univariable model fit was better with a 
restricted cubic spline for the BP parameter than with 
a linear BP term (likelihood ratio test P=0.04 for SBP; 
P<0.001 for DBP; Figure III in the Data Supplement). 
Model fit was most optimal for SBP (Akaike Informa-
tion Criterion 11 528 for SBP, 11 566 for DBP). In the 
adjusted model, the nonlinear relationship between SBP 
and functional outcome was J-shaped, with an inflection 
point at the median value of SBP: 150 mm Hg (Figure 2). 
For DBP, the relationship with functional outcome was 
also J-shaped with an inflection point at 81 mm Hg, the 
median value of DBP (Figure 2).
In the analysis adjusted for age, history of hyperten-
sion and NIHSS at baseline, higher SBPs (above the 
median of 150 mm Hg) were associated with increased 
odds of poor functional outcome (adjusted common 
odds ratio 1.09 per 10 mm Hg [95% CI, 1.04–1.15]), but 
lower SBPs (below the median of 150 mm Hg) were not 
(adjusted common odds ratio 1.00 per 10 mm Hg [95% 
CI, 0.95–1.06]; Table 2). Similarly, higher but not lower 
DBPs from the median value of 81 mm Hg were asso-
ciated with increased odds of poor functional outcome 
(Table II in the Data Supplement). The relation between 
SBP and functional outcome (shift analysis) was not 
modified by successful reperfusion (P for interac-
tion=0.47 and 0.73 for SPB<150 mm Hg and SBP≥150 
mm Hg, respectively).
Admission BP and Mortality, 24 to 48 Hours 
NIHSS, sICH, and Successful Reperfusion
The relations of SBP with mortality and NIHSS at 24 to 48 
hours were J-shaped with an inflection value at the median 
value of 150 mm Hg, whereas the relations between SBP 
and sICH and successful reperfusion (extended Throm-
bolysis in Cerebral Infarction score 2B-3) were linear 
(Figure 3). Higher SBPs above the median value of 150 
mm Hg were associated with increased odds of mortality 
and a higher NIHSS after 24 to 48 hours, whereas lower 
SBPs below 150 mm Hg were not (Table 2). Higher SBP 
was associated with a nonsignificant tendency towards 
an increased risk of sICH (Table 2). This association was 
not modified by successful reperfusion. Higher SBP was 
associated with decreased odds of achieving success-
ful reperfusion (Table 2). This association persisted after 
adjustment for the presence of carotid stenosis of 50% 
or greater. Results for the relationship between DBP and 
secondary outcomes were similar (Table II and Figure IV 
in the Data Supplement).
DISCUSSION
In this prospective multicenter cohort study of 3180 
patients treated with EVT for acute ischemic stroke in 
the anterior circulation, the relations of baseline SBP and 
DBP with poorer functional outcome followed J-shaped 
curves, with inflection points at the median values of 150 
and 81 mm Hg, respectively. Higher SBPs and DBPs 
above the median values were associated with increased 
odds of poor functional outcome and mortality at 90 days. 
In line with this, higher SBPs and DBPs were associated 
with a decreased probability of successful reperfusion 
and a tendency towards more frequent sICH.
Table 2. Association of Baseline SBP With Clinical and Radiographic Outcomes in Univariable and Multivariable Analysis
SBP<150 mm Hg SBP≥150 mm Hg
Unadjusted Adjusted Unadjusted Adjusted
mRS score at 90 d (shift analysis towards poor outcome)* 0.89 (0.85 to 0.94) 1.00 (0.95 to 1.06) 1.15 (1.10 to 1.20) 1.09 (1.04 to 1.15)
mRS score 0–1 at 90 d* 1.08 (1.01 to 1.15) 1.00 (0.93 to 1.08) 0.89 (0.84 to 0.95) 0.92 (0.85 to 0.99)
mRS score 0–2 at 90 d* 1.11 (1.05 to 1.17) 0.97 (0.91 to 1.04) 0.87 (0.83 to 0.92) 0.92 (0.86 to 0.97)
mRS score 0–3 at 90 d* 1.10 (1.17 to 1.24) 1.02 (0.95 to 1.10) 0.86 (0.82 to 0.90) 0.92 (0.87 to 0.98)
mRS score 3–6 at 90 d* 0.90 (0.86 to 0.96) 1.03 (0.57 to 1.10) 1.15 (1.09 to 1.20) 1.09 (1.03 to 1.16)
Mortality at 90 d* 0.87 (0.82 to 0.93) 1.02 (0.94 to 1.10) 1.16 (1.10 to 1.21) 1.09 (1.03 to 1.16)
NIHSS at 24–48 h* −0.31 (−0.09 to −0.54) −0.02 (−0.25 to 0.20) 0.46 (0.27 to 0.65) 0.34 (0.15 to 0.53)
 SBP    
 Unadjusted Adjusted   
Symptomatic intracranial hemorrhage† 1.07 (1.01 to 1.14) 1.06 (0.99 to 1.13)   
Successful reperfusion (eTICI score 2B-3)† 0.96 (0.93 to 0.98) 0.97 (0.94 to 0.99)   
eTICI indicates extended Thrombolysis in Cerebral Infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; and 
SBP, systolic blood pressure.
*Adjusted β-coefficients, OR, and corresponding 95% CI per 10 mm Hg increase in SBP above or decrease below the median value of 150 mm Hg.
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A French study of 1332 patients treated with EVT 
also reported a J-shaped relationship between SBP 
and mortality, with a nadir at 157 mm Hg, and a nonlin-
ear relationship between SBP and functional outcome, 
with a threshold of >177 mm Hg for poor functional out-
come.8 This study also found no relation between low 
SBP and functional outcome, but SBP <110 mm Hg 
was associated with an increased risk of death. In vari-
ous other studies, U-shaped relations of BP with clinical 
outcomes have been reported for patients with any isch-
emic stroke,4,7,18,19 with both extremes of BP associated 
with poorer outcome, although the reported optimum 
SBPs varied substantially between studies, ranging from 
120 to 130 mm Hg7,19 to 156 to 220 mm Hg in another 
study.20 Other types of relationships (eg, linear) have also 
been described.21 This is likely due to heterogeneity in 
inclusion criteria and stroke subtypes.
We found a tendency towards increased occurrence 
of sICH in patients with higher SBP, albeit not reach-
ing statistical significance. In some previous studies of 
patients treated with intravenous alteplase or EVT, an 
association between high baseline SBP and the risk of 
sICH was found.7,9 The lack of statistical significance in 
our study might be due to lack of power since just 6% 
of the included patients had a sICH. Two other studies 
in patients treated with EVT or with ischemic stroke in 
general also failed to find an association between SBP 
and sICH.4,8
In our study, higher BPs were associated with a lower 
probability of successful reperfusion after EVT. This finding 
is in line with 2 previous studies in patients with a large 
vessel occlusion, which demonstrated that higher SBPs 
were associated with poor reperfusion after EVT with the 
MERCI device (Mechanical Embolus Removal in Cerebral 
Figure 3. Relationship of baseline systolic blood pressure (SBP) with probability of mortality 90 d poststroke, National 
Institutes of Health Stroke Scale (NIHSS) at 24–48 h poststroke, probability of symptomatic intracranial hemorrhage (sICH), 
probability of successful reperfusion.
Models fitted with a restricted cubic spline transformation with 3 knots (A and B) or linear model (C and D). The figures depict the probability of 
90-d mortality (A), NIHSS at 24–48 h poststroke (B), probability of sICH (C), and probability of successful reperfusion (D) with 95% CIs, for each 
level of baseline SBP. The ranges of the x-axes correspond to minimum and maximum values of SBP and diastolic blood pressure (DBP) in the 
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Ischemia)22 or with intravenous thrombolysis.23 While this 
may indicate that occlusions that are difficult to recanalize 
are associated with higher BP, it has also been hypothesized 
that clot removal may be more difficult due to the hydraulic 
forces imposed by higher BP.22 Patients with SBP≥150 had 
a higher rate of carotid stenosis ≥50% or occlusion at the 
symptomatic carotid bifurcation, which may have increased 
the difficulty of the EVT procedure and thereby resulted in 
lower reperfusion rates. However, the relationship between 
SBP and lower reperfusion persisted after adjusting for 
the presence of carotid stenosis or occlusion, suggesting 
other factors are at play. Finally, we found slightly longer 
onset-to-groin and onset-to-reperfusion times for patients 
with SBP≥150 mm Hg, which is most likely explained by 
either treatment of hypertension or a wait-and-see policy 
in patients with BPs of 185/110 mm Hg or higher before 
the start of intravenous thrombolysis.
Whether the relationship between baseline BP and 
functional outcome is dependent on successful reperfu-
sion remains unclear. High SBP could be deleterious in 
successfully reperfused patients due to higher incidence 
of sICH, or it could be beneficial in those patients due 
to improved collateral flow and prolonged penumbral 
sustenance before the procedure. In our study, reperfu-
sion status did not modify the relation between SBP and 
functional outcome, and the same applies to the relation 
between SBP and sICH. This is in line with the French 
study mentioned above, in which the association of SBP 
with functional outcome did not depend on the occurrence 
of successful recanalization.8 A recent multicenter interna-
tional study, including 306 patients with large vessel occlu-
sion, found that the relationship between BP and functional 
outcome was modified by reperfusion status. In patients 
with successful reperfusion, high SBP was associated with 
less infarct growth and better functional outcome, possibly 
though improved collateral flow. This was not the case for 
those without successful reperfusion.24 These results were 
contradictory to a recent multicenter international study of 
1245 successfully recanalized patients, which found an 
association between high admission SBP on the one hand 
and a higher risk of sICH and a lower chance of good func-
tional outcome on the other.25 The latter study only included 
patients in whom successful reperfusion was achieved and 
therefore, effect modification by reperfusion status was not 
investigated, which limits the interpretation of this finding.
Most previous trials of BP lowering in patients with isch-
emic stroke have shown that treatment of hypertension in 
the first days after stroke onset does not reduce the risk of 
death or dependence.26 However, these trials did not assess 
very early BP modification before reperfusion therapy, and 
most were performed before EVT was implemented in 
routine clinical practice. One recently published phase III 
trial, RIGHT-2 (Rapid Intervention With Glyceryl Trinitrate 
in Hypertensive Stroke Trial), investigated BP lowering in 
a prehospital setting with nitroglycerin. Although moderate 
BP lowering did not result in improved functional outcome, 
this trial included patients with any ischemic stroke and only 
2% of patients in the nitroglycerin group were eventually 
treated with mechanical thrombectomy.27 While our find-
ings imply that very early BP lowering may be beneficial 
in stroke patients eligible for EVT, it is important to stress 
that our results do not prove a direct causal relationship 
between high BP and poor clinical outcomes. However, it 
is worthwhile to further explore early BP modification in 
randomized trials. This is currently done in the trials MR 
ASAP (Multicentre Randomised Trial of Acute Stroke 
Treatment in the Ambulance With a Nitroglycerin Patch)28 
and INTERACT4 (Intensive Blood Pressure Reduction in 
Acute Cerebral Hemorrhage Trial).29
Three limitations of the current study are worth men-
tioning. First, no eligibility log was available to assess 
whether EVT was withheld for reasons related to base-
line BP. Second, use of antihypertensive treatment in 
the emergency department was not documented, which 
limits our ability to assess the relationship of pre-EVT 
BP with outcomes. In addition, the documentation of a 
single SBP and DBP increases the risk of measurement 
error. The major strength of our study is the large data-
set with detailed and near-complete data. Our results 
represent an unselected cohort of EVT-treated patients 
in routine clinical practice, which improves generalizabil-
ity of our findings. A relatively large number of patients 
with poor or absent collaterals were treated, as well as 
patients with high baseline BPs, which emphasizes that 
patients with poor prognostic factors were not systemi-
cally deemed ineligible for EVT.
In summary, we found an association of higher admis-
sion SBPs and DBPs with poor clinical outcomes and 
lower probability of successful reperfusion in patients 
with ischemic stroke treated with EVT. Our results under-
score the potential for early BP modification in patients 
eligible for EVT, which could be the focus of future ran-
domized controlled trials.
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